|Home | About | Journals | Submit | Contact Us | Français|
Under physiological conditions, perivascular adipose tissue (PVAT) attenuates agonist‐induced vasoconstriction by releasing vasoactive molecules including hydrogen peroxide, angiotensin 1–7, adiponectin, methyl palmitate, hydrogen sulfide, NO and leptin. This anticontractile effect of PVAT is lost under conditions of obesity. The central mechanism underlying this PVAT dysfunction in obesity is likely to be an ‘obesity triad’ (consisting of PVAT hypoxia, inflammation and oxidative stress) that leads to the impairment of PVAT‐derived vasoregulators. The production of hydrogen sulfide, NO and adiponectin by PVAT is reduced in obesity, whereas the vasodilator response to leptin is impaired (vascular leptin resistance). Strikingly, the vasodilator response to acetylcholine is reduced only in PVAT‐containing, but not in PVAT‐free thoracic aorta isolated from diet‐induced obese mice, indicating a unique role for PVAT in obesity‐induced vascular dysfunction. Furthermore, PVAT dysfunction has also been observed in small arteries isolated from the gluteal/visceral fat biopsy samples of obese individuals. Therefore, PVAT may represent a new therapeutic target for vascular complications in obesity. A number of approaches are currently being tested under experimental conditions. Potential therapeutic strategies improving PVAT function include body weight reduction, enhancing PVAT hydrogen sulfide release (e.g. rosiglitazone, atorvastatin and cannabinoid CB1 receptor agonists) and NO production (e.g. arginase inhibitors), inhibition of the renin–angiotensin–aldosterone system, inhibition of inflammation with melatonin or cytokine antagonists, activators of AMP‐activated kinase (e.g. metformin, resveratrol and diosgenin) and adiponectin releasers or expression enhancers.
This article is part of a themed section on Molecular Mechanisms Regulating Perivascular Adipose Tissue – Potential Pharmacological Targets? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.20/issuetoc
|Other protein targets a||Nuclear hormone receptors d|
|Adipo1 receptor||Catalytic receptors e|
|GPCRs b||Leptin receptor|
|β3 adrenoceptor||Enzymes f|
|Ang 1‐7 receptor (MAS1)||ACE|
|Voltage‐gated ion channels c||Akt (PKB)|
|BKCa (KCa1.1) channel||CBS|
|IKCa (KCa3.1) channel||eNOS|
|KATP (Kir6.1) channel||PKG|
|KCNQ (Kv7.1) channel||sGC|
|SKCa (KCa2.1) channel|
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (a,b,c,d,e,fAlexander et al., 2015a,b,c,d,e,f).
The central role of the cardiovascular system is the transportation of oxygen, nutrients, biomolecules and signalling molecules to organs, tissues and cells. In addition, the circulation system is important in host defence by the immune system and in blood haemostasis/coagulation (Daiber et al., 2017). A dysregulation of vascular function may result in increased peripheral vascular resistance and blood pressure. Furthermore, vascular dysfunction promotes atherogenesis, and exacerbates insulin resistance by limiting the nutritive flow downstream in the microcirculation (Yudkin et al., 2005; Greenstein et al., 2009; Fuster et al., 2016).
For decades, the endothelium has been the focus of vascular research. In recent years, however, the importance of other vascular cells has been increasingly recognized, including vascular smooth muscle cells (VSMCs) (Lacolley et al., 2012), adventitia cells (Stenmark et al., 2013; Wu et al., 2015) and cells in the perivascular adipose tissue (PVAT). Moreover, communications exist between the different vascular cells and between the different layers of the vascular wall (Campbell et al., 2012). Therefore, the vascular wall should be regarded as a whole rather than separate layers. The present article focusses on the role of PVAT in regulating vascular function.
PVAT surrounds large arteries and veins, small and resistance vessels, and skeletal muscle microvessels. Other microvasculatures and the cerebral vasculature are free of PVAT (Brown et al., 2014; Gil‐Ortega et al., 2015). In contrast to humans and other large experimental animals (including rabbits and pigs), the murine coronary artery is without PVAT (Brown et al., 2014). Large vessels (such as the saphenous vein) are separated from PVAT by an anatomical barrier that is rich in collagen bundles, elastin networks, VSMCs, fibroblasts, autonomic nerve endings and vasa vasorum (Ahmed et al., 2004). In small vessels and microvessels, however, PVAT is an integral part of the vascular wall without laminar structures or any organized barrier separating PVAT from the adventitia (Szasz and Webb, 2012; Gil‐Ortega et al., 2015).
It is proposed that factors released by the PVAT reach the medial and endothelial layer of blood vessels either by direct diffusion or via the vasa vasorum (Gil‐Ortega et al., 2015). Another possible way for PVAT‐derived factors to reach the inner layers of the vascular wall is via the small media conduits, a dense reticular network of collagenous conduits connecting the medial layer with the underlying adventitia (Grabner et al., 2009; Campbell et al., 2012). These conduits enable soluble molecules to traffic between the PVAT/adventitia and media/intima.
In a murine model with VSMC‐specific PPAR‐γ deletion, the animals are completely devoid of PVAT in the aortic and mesenteric regions. In contrast, interscapular brown adipose tissue (BAT) and gonadal/inguinal/subcutaneous white adipose tissue (WAT) in these animals remain intact. These results indicate that the origin of the adipocytes in the PVAT is different from those in WAT and BAT (Chang et al., 2012; Brown et al., 2014). This notion is consistent with a previous observation that PVAT is a functionally specialized type of adipose tissue and PVAT adipocytes differ inherently in developmental and secretory properties from adipocytes in other fat depots (Chatterjee et al., 2009). Indeed, PVAT adipocytes are likely to arise from VSMC progenitors (Brown et al., 2014; Omar et al., 2014; Gil‐Ortega et al., 2015).
Importantly, regional phenotypic and functional differences exist among PVAT depots (Brown et al., 2014; Gil‐Ortega et al., 2015). Depending on the vascular bed, PVAT can be WAT‐like (e.g. murine mesenteric PVAT), BAT‐like (e.g. PVAT of the murine thoracic aorta) or mixed adipose tissue (e.g. PVAT of the murine abdominal aorta) and may have different vascularization, innervation and adipokine profiles (Szasz and Webb, 2012; Padilla et al., 2013; Brown et al., 2014; Gil‐Ortega et al., 2015; Drosos et al., 2016; Victorio et al., 2016b).
The morphological properties of PVAT in other species are less well‐defined than murine PVAT. Human coronary PVAT exhibits a histological appearance and gene expression pattern more consistent with WAT rather than BAT (Chatterjee et al., 2009; 2013).
PVAT plays a role in intravascular thermoregulation (Chang et al., 2012), vascular inflammation (Chatterjee et al., 2013), VSMC proliferation (Miao and Li, 2012; Ozen et al., 2015), the development of atherosclerosis (Greif et al., 2009; Verhagen and Visseren, 2011; Chang et al., 2012; Kawahito et al., 2013; van Hinsbergh et al., 2015; Gomez‐Hernandez et al., 2016) and hypertension (Galvez et al., 2006; Lee et al., 2011; Chang et al., 2013). The present article focuses on the role of PVAT in regulating vascular function under physiological conditions as well as in obesity.
A role for PVAT in vascular function was first indicated by the observation that PVAT decreased the contractile responses to noradrenaline in rat aorta (Soltis and Cassis, 1991). Now, it is known that PVAT attenuates the vascular responsiveness to several (hormonal) agonists, including phenylephrine, angiotensin II (Ang II), 5‐HT and endothelin‐1 (ET‐1) (Gollasch, 2012; Szasz and Webb, 2012).
PVAT may regulate vascular tone by releasing bioactive molecules, which can be regarded as an endocrine‐related effect. In addition, PVAT also exerts a more direct, local effect on the vascular wall via paracrine mechanisms. The PVAT is composed mainly of adipocytes and releases a wide range of biologically active molecules that modulate vascular function (Szasz and Webb, 2012). Factors that mediate the anticontractile effects of PVAT are referred to as adipocyte‐derived relaxing factor (ADRF) (Lohn et al., 2002; Gollasch, 2012), or perivascular‐derived relaxing factors (PVRF) (Lee et al., 2011).
The mechanism of action of some ADRF has been shown to rely on the opening of smooth muscle K+ channels, especially the KCNQ‐type of the voltage‐gated (Kv) K+ channels (Lohn et al., 2002; Gollasch, 2012), whereas ATP‐dependent K+ (KATP) channels have only minor effects (Schleifenbaum et al., 2010; Gil‐Ortega et al., 2015). Indeed, pharmacological openers of KCNQ channels mimic the effects of ADRF in spontaneously hypertensive rats as well as in a mouse model of metabolic syndrome (the New Zealand Obese mouse) (Zavaritskaya et al., 2013; Tano et al., 2014).
The identity of ADRF/PVRF is a matter of ongoing debate and it is likely to be a combination of several different molecules, depending on the stimulus applied, the vascular bed examined, and the phenotypic state of the PVAT (Figure 1).
A number of PVAT‐derived biologically active molecules with vascular effects have been identified so far; these include adipokines (e.g. leptin, adiponectin, omentin, visfatin, resistin and apelin), cytokines/chemokines [e.g. IL‐6; TNF‐α; monocyte chemoattractant protein‐1 (MCP‐1) and plasminogen activator inhibitor−1], some gaseous molecules (e.g. NO and H2S), prostacyclin, Ang 1–7, Ang II, methyl palmitate, ET‐1 and ROS (e.g. superoxide, H2O2) (Gollasch, 2012; Szasz and Webb, 2012; Almabrouk et al., 2014; Tano et al., 2014). Some of these are potential candidates for ADRF/PVRF.
Bioassay experiments indicate that PVAT can exert its anticontractile effects through two distinct mechanisms: by releasing transferable relaxing factors and by an endothelium‐independent mechanism involving H2O2 and subsequent activation of soluble guanlylyl cyclase (sGC) (Gao et al., 2007).
PVAT‐derived H2O2 has been shown to be one of the factors mediating the endothelium‐independent anticontractile property of PVAT. Because H2O2 is membrane‐permeable, PVAT‐derived H2O2 can easily diffuse to underlying smooth muscle cells and induce vasodilatation by acting as a non‐NO sGC activator (Gao et al., 2007; Fernandez‐Alfonso et al., 2013). Moreover, H2O2 can directly activate cGMP‐dependent PKGIα independently of cGMP (Burgoyne et al., 2007).
The PVAT‐derived transferable relaxing factors have been suggested by later studies to include Ang 1–7 (Lee et al., 2009; Gil‐Ortega et al., 2015), adiponectin (Greenstein et al., 2009; Lynch et al., 2013; Weston et al., 2013) and methyl palmitate (Lee et al., 2011).
All components of the renin–angiotensin system (RAS), except renin, are found in aortic and mesenteric PVAT, including angiotensinogen, ACE, ACE2, chymase, Ang I, Ang II, AT1 and AT2 receptors (Galvez‐Prieto et al., 2008), as well as Ang 1–7 (Lee et al., 2009).
Ang 1–7 produced by PVAT is one of the diffusible factors that induces vasodilatation indirectly through an endothelium‐dependent mechanism. It binds to the endothelial Ang 1–7 receptor (Mas) and thereby stimulates endothelial NO production. The latter acts as a hyperpolarizing factor mediated through calcium‐dependent K+ (KCa) channels to cause relaxation of the blood vessels (Lee et al., 2009; Gil‐Ortega et al., 2015).
PVAT also produces the vasoconstrictor Ang II (Huang et al., 2010; Lu et al., 2010). The release of Ang II from PVAT is enhanced in spontaneously hypertensive rats compared with normotensive rats (Lee et al., 2011). PVAT‐specific RAS activation has been recently implicated in the development of atherosclerosis associated with chronic kidney disease (Kawahito et al., 2013).
It is controversial whether adiponectin is an ADRF/PVRF. Aortae and mesenteric arteries from adiponectin‐knockout mice have been shown to maintain their anticontractile properties (Fesus et al., 2007). However, recent studies demonstrate that the anticontractile activity of PVAT is significantly reduced in adiponectin‐deficient mice (Lynch et al., 2013; Withers et al., 2014b), and the anticontractile function of PVAT can be largely abolished by blocking adiponectin receptors (Greenstein et al., 2009; Lynch et al., 2013). Undisputedly, adiponectin is produced in adipose tissues (also in PVAT) and is a potent vasodilator. Circulating adiponectin has been shown to be directly related to endothelial function in the general population (Saarikoski et al., 2010), although some controversy exists (Ran et al., 2010). Adiponectin is an independent predictor of endothelial function in a well‐phenotyped cohort of patients with coronary artery disease (Margaritis et al., 2013), and genome‐wide association studies have revealed that genetically‐determined lower circulating adiponectin levels are related to worse endothelial function (Margaritis et al., 2013).
Adiponectin induces vasodilatation through multiple mechanisms. (i) Adiponectin can act directly on VSMC, causing myocyte hyperpolarization by activating TRPM4 channels followed by the opening of large‐conductance Ca2 +‐activated K+ channels (BKCa) (Lynch et al., 2013; Weston et al., 2013). (ii) Adiponectin stimulates NO release from adjacent adipocytes through paracrine mechanisms. This adipocyte‐derived NO potentiates BKCa opening in VSMC (Weston et al., 2013). (iii) Adiponectin can enhance endothelial NO production by stimulating the binding of HSP90 to endothelial NOS (eNOS) (Xi et al., 2005), by enhancing eNOS phosphorylation at serine 1177, which is catalysed by either PI3K/Akt (Xi et al., 2005; Cerqueira et al., 2012; Margaritis et al., 2013) or AMP‐activated kinase (AMPK) (Withers et al., 2014a), and by increasing the biosynthesis of tetrahydrobiopterin, an essential cofactor of eNOS (Margaritis et al., 2013). Consistently, adiponectin‐knockout mice exhibit reduced eNOS phosphorylation at serine 1177 and impaired endothelial function (Cao et al., 2009).
Moreover, adiponectin produced in PVAT has also been shown to exert a paracrine effect on the underlying arterial wall by suppressing NADPH oxidase activity via a PI3K/Akt‐mediated inhibition of Rac1 and down‐regulation of p22phox gene expression (Antonopoulos et al., 2015b).
Importantly, adiponectin plays a central role in mediating crosstalk between different vascular cells (Figure 1). Through paracrine mechanisms, adiponectin from PVAT adipocytes regulates NO production in adjacent adipocytes (Withers et al., 2014a,b). As mentioned above, PVAT adiponectin induces vasodilatation by stimulating endothelial cells and VSMC hyperpolarization, and reduces vascular oxidative stress by inhibiting NADPH oxidase activity. As a feedback mechanism, oxidative stress in the vascular wall up‐regulates PVAT adiponectin expression by activating PPARγ (Antonopoulos et al., 2015b).
A study using the superfusion bioassay cascade technique has revealed that PVAT releases a lipophilic, heat‐stable factor that causes vasodilatation by opening the Kv channels on VSMC (Lee et al., 2011). This factor has been identified as palmitic acid methyl ester (PAME). PAME derives from PVAT adipocytes and is released from PVAT spontaneously in Ca2 +‐containing solutions. PAME release is inhibited in Ca2 +‐free conditions and enhanced by the calcium ionophore A23187 (Lee et al., 2011). The anticontractile function of PVAT was found to be reduced in spontaneously hypertensive rats as well as the release of PAME; both mechanisms contributing to the pathogenesis of hypertension (Lee et al., 2011).
H2S is synthesized from L‐cysteine by cystathionine‐β‐synthase (CBS) or cystathionine‐γ‐lyase (CSE), and is enzymatically metabolized in mitochondria by sulfide:quinone oxidoreductase (Papapetropoulos et al., 2015). In endothelial cells, H2S is produced by CSE and is considered the most likely candidate for endothelium‐derived hyperpolarizing factor (EDHF) (Yang et al., 2008; Wang et al., 2015). In an autocrine mode, endothelial H2S activates small and intermediate conductance calcium‐dependent K+ channels on endothelial cells (Mustafa et al., 2011). The resulting hyperpolarization of endothelial cells can be transmitted to VSMC by electrical coupling through myoendothelial gap junction or by increased K+ efflux, which then activates VSMC inwardly‐rectifying K+ channels and/or Na+/K+‐ATPase (Feletou and Feletou and Vanhoutte, 2009; Jamroz‐Wisniewska et al., 2014). In a paracrine mode, endothelium‐generated H2S can directly induce VSMC hyperpolarization by opening KATP channels in these cells (Wang et al., 2015).
Recent studies indicate that PVAT also produces H2S via CSE activity, and that PVAT‐derived H2S is involved in the anticontractile effect of PVAT on adjacent vessels (Fang et al., 2009; Schleifenbaum et al., 2010; Kohn et al., 2012). H2S donors produce a strong vasorelaxation of VSMC by opening the KCNQ‐type Kv channels (Kohn et al., 2012), perhaps also partly by opening KATP channels (Jamroz‐Wisniewska et al., 2014). The anticontractile effect of PVAT can be reduced by inhibition of CSE (but not CBS) in aortas from rats but not from mice, indicating that endogenous H2S is an ADRF from rat (but not mouse) aortic PVAT (Kohn et al., 2012).
It has been demonstrated that the anti‐contractile effects of PVAT cannot be blocked by inhibiting NOS (Lohn et al., 2002). It was, therefore, concluded that that the PVAT‐derived relaxing factor was not NO. Now, it is clear that ADRF represents more than one single molecule, and blockade of NO synthesis alone may not be sufficient to prevent the effect of PVAT. Recent studies demonstrate that NO is produced within PVAT and this PVAT‐derived NO contributes to the anticontractile effect of PVAT (Dashwood et al., 2007; Gil‐Ortega et al., 2010; Withers et al., 2014b; Aghamohammadzadeh et al., 2015; Bussey et al., 2016; Xia et al., 2016; Victorio et al., 2016b).
Immunohistochemistry analysis has shown eNOS staining in adipocytes as well as endothelial cells of the capillaries and vasa vasorum within PVAT (Dashwood et al., 2007). The NO produced in PVAT can be directly visualized in situ with fluorescence imaging (Gil‐Ortega et al., 2010; Xia et al., 2016; Victorio et al., 2016b). Adipocyte‐derived NO is supposed to be released into the interstitial fluid and to diffuse into the capillaries and adjacent arterioles causing vasodilatation (Mastronardi et al., 2002).
In myograph experiments, NG‐nitro‐L‐arginine methyl ester (L‐NAME) induces vasoconstriction, which reflects the amount of basal NO released. The L‐NAME‐induced vasoconstriction in small arteries isolated from visceral fat of healthy individuals is reduced by the removal of PVAT (Virdis et al., 2015), indicating that PVAT contributes to vascular NO production. In PVAT‐intact, endothelium‐denuded rat mesenteric arteries, eNOS inhibitors significantly enhance noradrenaline‐induced contractions, indicating that PVAT‐derived NO contributes to the anticontractile effect of PVAT independently of the endothelium (Aghamohammadzadeh et al., 2015; Bussey et al., 2016).
Multiple mechanisms may mediate the vasorelaxant action of PVAT‐derived NO (Figure 1): (i) PVAT NO may diffuse into adjacent smooth muscle cells and induce vasodilatation by stimulating cGMP synthesis; (ii) NO derived from eNOS in adipocytes positively regulates adiponectin release (Withers et al., 2014b); and (iii) adipocyte‐derived NO modulates BKCa in smooth muscle cells and potentiates hyperpolarization (Weston et al., 2013).
Leptin is mainly produced by adipocytes and plays important roles in regulating appetite, energy expenditure, inflammation and immune responses (Molica et al., 2015). At the clinical level, its role in coronary heart disease still remains controversial (Antonopoulos et al., 2015a). Leptin is also produced by PVAT (Dashwood et al., 2011; Galvez‐Prieto et al., 2012), although it is not considered an ADRF. The anticontractile effect of PVAT is maintained in the Zucker fa/fa rats that lack functional leptin receptors (Lohn et al., 2002).
Under physiological conditions, leptin has no acute effect on blood pressure because it activates both pressor (sympathetic nervous system) and depressor (vasodilatation and natriuresis) mechanisms in a balanced manner (Jamroz‐Wisniewska et al., 2014). Through central mechanisms, leptin increases sympathetic nervous activity to the kidney, the adrenal gland, the hindlimbs and to BAT (Haynes et al., 1997; Mark, 2013). However, leptin also directly induces relaxation of blood vessels. Acute infusion of leptin has no significant effect on blood pressure in rats (Haynes et al., 1997) or in humans (Brook et al., 2007). Interestingly, leptin's dual effect on blood pressure can be revealed by various procedures (Fruhbeck, 1999). When NO synthesis is inhibited, leptin administration to Wistar rats produces a statistically significant increase in blood pressure, whereas a hypotensive response is induced by leptin in the presence of ganglionic blockade (Fruhbeck, 1999).
Leptin may cause vasodilatation in different vessels through different mechanisms. In large arteries (e.g. the aorta), leptin induces an endothelium‐dependent vasodilatation that is the result of the release of NO (Lembo et al., 2000). Leptin‐stimulated endothelial NO production is mediated by the sequential activation of an AMPKα1‐Akt‐eNOS pathway leading to eNOS phosphorylation at serine 1177 (Vecchione et al., 2002; Procopio et al., 2009). In small arteries (e.g. mesenteric arteries), both NO and EDHF play a role in leptin‐induced relaxation (Lembo et al., 2000; Jamroz‐Wisniewska et al., 2014). The leptin‐induced vasorelaxation mediated by EDHF, is at least in part, a result of CSE‐dependent H2S production in endothelial cells (Jamroz‐Wisniewska et al., 2014). In human saphenous vein and internal mammary artery (Momin et al., 2006), and to a small extent in rat mesenteric artery (Jamroz‐Wisniewska et al., 2014), leptin induces an endothelium‐independent vasodilatation that is mediated by hyperpolarization of the VSMCs.
In coronary artery bypass surgeries, saphenous vein grafts with PVAT exhibit superior patency rate and better preserved intimal, medial and adventitial architecture compared with those without PVAT (Verma et al., 2014; Kopjar and Dashwood, 2016), demonstrating the beneficial effects of PVAT in vivo. Leptin concentrations in the PVAT of saphenous vein grafts are within the concentration range causing relaxation of bypass conduits (Dashwood et al., 2011). It has therefore been proposed that PVAT‐derived leptin may play a role in preserving a ‘healthy graft’ by reducing vasospasm at graft harvesting as well as after its implantation into the coronary circulation (Dashwood et al., 2011; Dashwood and Tsui, 2013). However, there is no evidence for a causal link between PVAT‐derived leptin and the superior performance of PVAT‐containing grafts. The beneficial effects of PVAT in this regard can also be attributed to other vasoactive molecules released by PVAT.
Obesity has numerous adverse effects on the circulation and cardiovascular structure and function (Lavie et al., 2009). Obese patients are more likely to develop hypertension and cardiomyopathy, and have a higher risk of stroke (Lavie et al., 2009). Obesity and atherosclerosis have long been linked in observational studies. The two conditions share similar pathophysiological pathways, including dyslipidaemia and chronic inflammatory processes (Rocha and Libby, 2009).
In humans, the thoracic peri‐aortic fat mass correlates with hypertension, diabetes and aortic/coronary calcification, when corrected for body‐mass index (but not if corrected for visceral adipose tissue) (Lehman et al., 2010). Clinical studies have shown that abdominal adiposity is associated with vascular dysfunction, as measured by flow‐mediated dilation of the brachial artery (Brook et al., 2001; Hamburg et al., 2008). In human small arteries, the anticontractile effect of PVAT is completely lost in obese patients with metabolic syndrome (Greenstein et al., 2009).
In animal models of obesity, the PVAT mass and adipocyte size are increased (Marchesi et al., 2009; Ketonen et al., 2010), which is accompanied by other structural modifications in the PVAT (Szasz and Webb, 2012). The anticontractile effect of PVAT is completely lost in the mouse model of diet‐induced obesity (Ketonen et al., 2010) and genetic model of metabolic syndrome (the New Zealand obese mouse) (Marchesi et al., 2009), or significantly reduced in the ob/ob mice (Agabiti‐Rosei et al., 2014). In addition, the PVAT of obese animals inhibits the vasodilator responses to acetylcholine (Ketonen et al., 2010; Ma et al., 2010; Xia et al., 2016). Obesity‐induced dysfunctions of the PVAT correlate with a rise in blood pressure in rodent models of diet‐induced obesity (Aghamohammadzadeh et al., 2015), demonstrating the importance of PVAT function in vascular pathology in vivo.
Based on current research results, an ‘obesity triad’ consisting of PVAT hypoxia, inflammation and oxidative stress can be proposed as the central mechanism in obesity‐induced PVAT dysfunction (Figure 2). Cellular hypoxia in PVAT is thought to be due to adipocyte hypertrophy twinned with reductions in capillary density and angiogenesis (Pasarica et al., 2009; Fuster et al., 2016). Hypoxia, in turn, stimulates the production of inflammatory cytokines and chemokines from PVAT adipocytes and infiltrating macrophages (Greenstein et al., 2009). Importantly, PVAT inflammation precedes macrophage infiltration. A short‐term high‐fat diet (HFD) fed to mice for 2 weeks results in a marked up‐regulation of pro‐inflammatory leptin and MIP1α (also known as CCL3), and down‐regulation of anti‐inflammatory PPARγ (Chatterjee et al., 2009; Cheang et al., 2015) and adiponectin (Chatterjee et al., 2009). At this early stage, there are no signs of macrophage infiltration in PVAT, although the infiltration of T cells in PVAT is likely (Chatterjee et al., 2009). Thus, the infiltration of macrophages may be a response to PVAT inflammation, probably triggered by chemokines such as MCP‐1. PVAT adipocytes produce 50‐fold more MCP‐1 than adipocytes from other fat regional depots (Chatterjee et al., 2009), and a HFD further enhances MCP‐1 expression in aortic PVAT (Ketonen et al., 2010; Xia et al., 2016). Macrophages, in turn, potentiate the PVAT inflammatory response and enhance the activity of NADPH oxidase, a major source of superoxide anion in the vasculature that is also expressed in PVAT (Gao et al., 2006). Indeed, the expression of p67phox (Ketonen et al., 2010) and Nox2 (Xia et al., 2016), subunits in the NADPH oxidase complex, is increased in the PVAT of obese mice. Moreover, HFD‐fed mice also show a reduced SOD3 expression and glutathione levels in their mesenteric PVAT (Gil‐Ortega et al., 2014). The resulting oxidative stress further enhances PVAT inflammation, leading to a vicious circle (Figure 2).
In support of this concept, PVAT dysfunction induced by in vitro incubation with aldosterone (Withers et al., 2011) or cytokines (Greenstein et al., 2009) can be fully restored using a combination of catalase and superoxide dismutase. Ex vivo incubation with superoxide dismutase and catalase also restores the anticontractile function of PVAT from obese individuals (Aghamohammadzadeh et al., 2013, 2015). Similarly, hypoxia‐induced PVAT dysfunction can be normalized by in vitro incubation with an anti‐TNF‐α antibody or an anti‐IL‐6 antibody (Greenstein et al., 2009), confirming the role of inflammation and oxidative stress in PVAT dysfunction. In agreement with this, ex vivo incubation with the anti‐TNF‐α antibody infliximab improves NO production in small arteries isolated from obese patients. Moreover, this effect is more pronounced in PVAT‐containing vessels than in PVAT‐free arteries (Virdis et al., 2015). The removal of macrophages prevents hypoxia‐ and aldosterone‐induced PVAT dysfunction (Withers et al., 2011). Also, preventing macrophage infiltration ameliorates PVAT dysfunction in mice with diet‐induced obesity (Wang et al., 2012).
Local inflammation in PVAT is potentiated by systemic inflammation and inflammation of other adipose tissues in the obesity state, where adipose tissue mass can range from 30 to 50% of total body mass (Fuster et al., 2016). Adipose tissue is the major source of IL‐6, contributing as much as one third of total circulating IL‐6 (Mohamed‐Ali et al., 1997). Similarly, leptin is an adipose tissue‐specific adipokine. It is highly expressed in adipocytes, and circulating leptin levels increase in parallel with adipose tissue mass (Fuster et al., 2016). Thus, IL‐6, leptin and other pro‐inflammatory factors released from other adipose tissues can reach PVAT via the circulation and contribute to PVAT inflammation.
The obesity triad of hypoxia, inflammation and oxidative stress in PVAT ultimately leads to a dysregulated production/secretion of adipokines and cytokines. In PVAT of HFD‐fed mice, pro‐inflammatory adipokines/cytokines (e.g. leptin, IL‐6, TNF‐α and interferon‐γ) are up‐regulated, whereas anti‐inflammatory adipokines/cytokines (e.g. adiponectin and IL‐10) are down‐regulated (Chatterjee et al., 2009; Ketonen et al., 2010; Xia et al., 2016). The resulting exacerbation of inflammation and oxidative stress promotes a dysregulation of biomolecule production in the PVAT and vascular dysfunction (Almabrouk et al., 2014; Gil‐Ortega et al., 2014; Omar et al., 2014; Molica et al., 2015).
Under conditions of obesity, the synthesis, secretion or action of PVAT‐derived vasoactive molecules are impaired (Figure 2).
Experimental obesity induced by a high‐calorie (but not high‐fat) ‘cafeteria’ diet is associated with a time‐dependent effect on PVAT‐produced H2S in rats. Feeding for 3 months results in obesity with signs of metabolic syndrome, whereas 1 month feeding leads to adiposity without insulin resistance. Interestingly, short‐term obesity (induced by 1 month of cafeteria diet) in rats increases production of H2S by PVAT and this is associated with an enhanced anticontractile effect of PVAT, whereas long‐term obesity (3 months on cafeteria diet) reduces H2S production and the anticontractile effects of PVAT (Beltowski, 2013). The enhanced H2S production in the early phase of obesity may represent a compensatory mechanism and result from reduced H2S oxidation due to hypoxia. In contrast, H2S production is decreased in long‐lasting obesity and metabolic syndrome because of a down‐regulation of the CSE enzyme in PVAT (Beltowski, 2013).
Plasma H2S levels are reduced in overweight people and patients with type 2 diabetes, independently of diabetes. Waist circumference has been shown to be an independent predictor of plasma H2S and remains an independent predictor of plasma H2S after adjustment for systolic blood pressure, microvascular function, insulin sensitivity, glycaemic control and lipid profile (Whiteman et al., 2010).
In humans, circulating adiponectin levels are decreased with increasing obesity (Weiss et al., 2004) and type 2 diabetes (Antonopoulos et al., 2015b). Hypoadiponectinemia is closely associated with endothelial dysfunction (Shimabukuro et al., 2003).
Reduced adiponectin levels are uniformly found in PVAT of obese subjects (Aghamohammadzadeh et al., 2013) and in PVAT samples from different animal models of obesity, including the ob/ob mice (Agabiti‐Rosei et al., 2014), the db/db mice (Meijer et al., 2013) and diet‐induced obese mice (Chatterjee et al., 2009).
A recent study has identified PPARγ as a positive regulator of adiponectin expression in PVAT (Antonopoulos et al., 2015b). Interestingly, PPARγ is down‐regulated in the PVAT of diet‐induced obese mice (Chatterjee et al., 2009); this may represent a molecular mechanism for the reduced adiponectin expression in PVAT found during obesity.
Furthermore, adiponectin secretion is also reduced during obesity. Normally, adiponectin secretion from PVAT adipocytes is fine‐tuned; the mechanisms include β3‐adrenoceptor stimulation (Weston et al., 2013), NO production and PKG activation (Withers et al., 2014b). Under conditions of obesity, adiponectin secretion is decreased, which may be attributable to β3 adrenoceptor desensitization, reduced NO production and PKG down‐regulation in PVAT adipocytes (Withers et al., 2014a).
Although an adaptive overproduction of NO from mesenteric PVAT has been observed at the early phase of diet‐induced obesity in C57BL/6J mice (Gil‐Ortega et al., 2010), a longer time on a HFD leads to a reduction in PVAT NO production (Aghamohammadzadeh et al., 2015; Xia et al., 2016).
Inhibition of NO synthesis enhances the agonist‐induced contraction of PVAT‐intact, endothelium‐denuded mesenteric arteries from healthy rats. However, this effect of NO synthesis inhibition is lost in PVAT‐intact vessel segments from diet‐induced obese animals (Aghamohammadzadeh et al., 2015; Bussey et al., 2016). These results indicate that the anticontractile effect of healthy PVAT is partially mediated by PVAT‐derived NO, whereas obesity reduces PVAT NO production to a level that is too low to be functionally relevant.
Consistent with these data, basal NO release has been shown to be reduced in small arteries from obese patients compared with non‐obese controls. Interestingly, this obesity‐induced reduction in basal NO production is only evident in PVAT‐containing but not in PVAT‐removed arteries (Virdis et al., 2015), supporting the concept that a reduced production of NO by PVAT is involved in the obesity‐induced loss of the anticontractile effect of PVAT.
Several molecular mechanisms may be responsible for the reduced PVAT NO production in obesity: (i) A reduced expression of eNOS has been reported in the mesenteric PVAT of diet‐induced obese rats (Bussey et al., 2016) and mice (Gil‐Ortega et al., 2014). (ii) In the PVAT of thoracic aorta from diet‐induced obese mice, however, we did not observe any changes in eNOS expression but have obtained evidence that the function of eNOS is impaired (eNOS uncoupling as well as reduced eNOS phosphorylation at serine 1177 residue) (Xia et al., 2016). (iii) The reduction in PVAT NO can also be partially attributed to a deficiency in PVAT adiponectin that normally stimulates eNOS activity in PVAT adipocytes (Weston et al., 2013).
Hyperleptinaemia in diet‐induced obesity leads to selective leptin resistance with preservation of leptin‐induced increases in renal sympathetic nerve activity and blood pressure despite resistance to the anorexic and weight‐reducing actions of leptin (Rahmouni et al., 2005; Coppari and Bjorbaek, 2012; Mark, 2013). Cerebroventricular administration of leptin antagonists significantly decreases mean arterial pressure and renal sympathetic nerve activity in diet‐induced obese rabbits, indicating that the central actions of leptin play a role in the elevation of blood pressure and renal sympathetic nerve activity induced by a HFD in rabbits (Lim et al., 2013). Similarly, the elevation in blood pressure induced by chronic leptin infusion can be prevented with combined α‐ and β‐adrenoceptor blockade (Shek et al., 1998; Carlyle et al., 2002).
Hyperleptinaemia shows a biphasic effect on vascular function. In the early stage of diet‐induced obesity (4 weeks), the NO‐mediated component of leptin‐induced relaxation of mesenteric artery is impaired, which is compensated for by an up‐regulation of EDHF‐mediated vasodilatation (Beltowski et al., 2010; Jamroz‐Wisniewska et al., 2014). Interestingly, the impaired NO component of leptin‐induced vasodilatation in obese rats can be restored by antagonizing the leptin receptors, indicating that hyperleptinaemia induces vascular leptin resistance in diet‐induced obesity. Consistently, the impairment of leptin‐induced, NO‐mediated vasodilatation can also be observed in rats treated for 8 days with exogenous leptin (Jamroz‐Wisniewska et al., 2014). In the later phase of obesity (3 months), both the NO‐ and EDHF‐mediated effects of leptin are reduced leading to an increase in blood pressure (Beltowski et al., 2009; Jamroz‐Wisniewska et al., 2014). Chronic hyperleptinaemia‐induced vascular leptin resistance (loss of leptin‐induced vasodilatation) has been shown both in vivo in anaesthetised dogs and ex vitro in coronary rings isolated from diet‐induced obese dogs (Knudson et al., 2005). Mechanistically, leptin‐induced endothelial dysfunction is associated with inflammation, oxidative stress and eNOS uncoupling (Korda et al., 2008).
Leptin levels are uniformly increased in diet‐induced obesity, not only in the blood but also in PVAT (Ketonen et al., 2010; Schroeter et al., 2013; Gil‐Ortega et al., 2014; Xia et al., 2016). In a mouse model of diet‐induced obesity, the up‐regulation of leptin in aortic PVAT is paralleled by a reduced anticontractile effect of PVAT and correlates with a loss of PVAT‐derived NO and PVAT eNOS (Gil‐Ortega et al., 2014).
Metabolic syndrome in Ossabaw miniature swine increases epicardial PVAT leptin protein and coronary leptin receptor expression. Coronary arteries from swine with metabolic syndrome display significant endothelial dysfunction that is markedly exacerbated by PVAT. A leptin antagonist reverses the metabolic syndrome effect of PVAT on endothelium‐dependent vasodilatation, indicating that epicardial PVAT‐derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome (Payne et al., 2010).
In a recent study, we analysed the vascular function of thoracic aorta isolated from diet‐induced obese C57BL/6J mice (Xia et al., 2016). Unexpectedly, the endothelium‐dependent, NO‐mediated vasodilator response to acetylcholine remained unchanged in aortas from mice fed a HFD for 20 weeks (Figure 3A). Even after varying the experimental conditions (60 or 45 kcal% fat; 20 or 12 weeks on a HFD), we did not observe any endothelial dysfunction in the PVAT‐free thoracic aorta of obese mice.
Strikingly, when the aortic PVAT was left in place, a clear reduction in the vasodilator response to acetylcholine was observed in the aorta of obese animals as compared with lean controls (Figure 3B). Acetylcholine‐induced vasodilatation in the mouse aorta (either with or without PVAT) can be completely blocked by inhibition of NO synthesis (Figure 3C), indicating that this response is NO‐dependent. Thus, the reduced vasomotor function in the aorta of HFD‐fed mice (Figure 3B) results from eNOS dysfunction in the PVAT, but not in the endothelium. Indeed, we found evidence for PVAT eNOS dysfunction in diet‐induced obese mice (Xia et al., 2016).
Notably, all the pathological changes (arginase induction, L‐arginine deficiency, Akt inhibition and reduced eNOS phosphorylation) in diet‐induced obese mice were observed only in the PVAT but not in the aorta itself (Xia et al., 2016). These data provide a compelling mechanistic explanation for our initial observation that vascular dysfunction in obese mice is only evident in PVAT‐containing aorta but not in PVAT‐free aorta. These findings further substantiate our hypothesis that the role of PVAT may be even more important than that of the endothelium in obesity‐induced vascular dysfunction under certain experimental settings.
Similar evidence also exists in studies with human samples. In small arteries isolated from obese patients, an ET‐1/NO imbalance is evident, which is associated with vascular dysfunction. Interestingly, the reduced NO availability and enhanced ET‐1 signalling in arteries from obese patients can be reversed by PVAT removal (Virdis et al., 2015), demonstrating the crucial role of PVAT in obesity‐induced vascular dysfunction.
The role of PVAT in regulating vascular function in humans has been studied by using either small arteries from gluteal/visceral fat biopsy samples or coronary bypass graft materials such as the internal mammary artery or the saphenous vein.
The anticontractile effect of human PVAT has been shown for the internal mammary artery (Gao et al., 2005; Malinowski et al., 2008; Foudi et al., 2011; Malinowski et al., 2013; Ozen et al., 2013), the saphenous vein (Ford et al., 2006; Dashwood et al., 2007, 2011; Foudi et al., 2011; Ozen et al., 2013) and for small arteries (Aghamohammadzadeh et al., 2013; Greenstein et al., 2009; Virdis et al., 2015).
Currently, PVAT‐removed graft materials are mostly used in coronary artery bypass operations. Intimal hyperplasia and vasospasm with a reduction in patency rate are common problems that occur after bypass surgery (Ozen et al., 2015). In this regard, saphenous vein grafts harvested by the ‘no‐touch’ technique with intact adventitia and PVAT have been shown to be superior to those obtained by open vein harvesting or endoscopic vein harvesting with adventitia and PVAT removed (Souza et al., 2001; Dashwood and Tsui, 2013; Dreifaldt et al., 2013; Verma et al., 2014; Kopjar and Dashwood, 2016). Unfortunately, there are yet no such clinical studies addressing the role of internal mammary artery PVAT in coronary artery bypass operations.
Obesity in humans is associated with endothelial dysfunction in vivo (Steinberg et al., 1996; Al Suwaidi et al., 2001; Grassi et al., 2010). In human small arteries taken from subcutaneous gluteal fat biopsies, the anticontractile effect of PVAT is shown to be completely lost in obese patients (Greenstein et al., 2009; Aghamohammadzadeh et al., 2013).
In obese patients, PVAT undergoes hypoxia, oxidative stress and inflammation, leading to the up‐regulation of pro‐inflammatory cytokines (e.g. TNF‐α) (Greenstein et al., 2009), enhanced ROS production, a down‐regulation of antioxidant enzymes (e.g. SOD1, peroxiredoxin‐1) (Aghamohammadzadeh et al., 2015) and reduced release of vasodilating adipokines (e.g. adiponectin) (Greenstein et al., 2009) as well as a decreased NO production from PVAT (Aghamohammadzadeh et al., 2015). Ex vivo incubation of arteries from obese individuals with superoxide dismutase and catalase restores the anticontractile effects of PVAT (Aghamohammadzadeh et al., 2013; 2015).
In small arteries isolated from visceral fat of obese patients, the expression of TNF‐α is increased both in the vascular wall and in PVAT (Virdis et al., 2015). This increase in TNF‐α reduces the production of adiponectin, triggers eNOS uncoupling by activating NADPH oxidase activity and stimulates ET‐1 generation. The resulting ET‐1/NO imbalance is implicated in obesity‐induced vascular dysfunction (Virdis et al., 2015). Moreover, the reduced NO availability and enhanced ET‐1 signalling in arteries from obese patients can be reversed by PVAT removal (Virdis et al., 2015), indicating that the vasorelaxant effect of PVAT under physiological conditions is transformed into an inflammatory pro‐contractile phenotype in obesity (Virdis et al., 2015).
Calorie restriction‐induced sustained weight loss in obese rats leads to an improvement in PVAT function associated with a reversal in obesity‐induced hypertension, the restoration of adipocyte size, PVAT eNOS function, PVAT TNF‐α expression and normalization of plasma adipokine levels, including leptin and insulin (Bussey et al., 2016).
In humans, bariatric surgery restores the anticontractile activity of PVAT in severely obese individuals (Aghamohammadzadeh et al., 2013). The normalization of PVAT function after surgery is accompanied by improvements in insulin sensitivity, serum glycaemic indexes, inflammatory cytokines, adipokine profile and systolic blood pressure together with increased PVAT adiponectin and NO bioavailability (Aghamohammadzadeh et al., 2013). Strikingly, these changes are evident despite the patients remaining obese (BMI declines from 51 before surgery to 38 after surgery) (Aghamohammadzadeh et al., 2013).
In familial hypercholesterolaemic pigs, exercise training significantly reduces the contractile response of left circumflex coronary artery to ET‐1. This effect has been shown to be independent of PAVT (Bunker and Laughlin, 2010).
Exercise training of Wistar rats for 8 weeks decreases plasma triglyceride levels with no effect on adipokine profiles. Exercise training up‐regulates the expression of eNOS in PVAT but not in the aorta. Exercise reduces the amount of thoracic PVAT without changing the effects of PVAT on relaxation or constriction (Araujo et al., 2015). However, this study was performed in healthy rats on normal chow. Future studies should investigate the effect of exercise training on PVAT function in obesity models.
A major mechanism for the PVAT eNOS dysfunction in experimental obesity is eNOS uncoupling due to a deficiency in L‐arginine, which is attributable to an up‐regulation of arginase found in PVAT of diet‐induced obese mice (Xia et al., 2016). Arginases are major L‐arginine‐consuming enzymes that metabolize L‐arginine to urea and L‐ornithine. The up‐regulation of arginase limits L‐arginine bioavailability for NO production and leads to eNOS uncoupling (Yang and Ming, 2013). An uncoupled eNOS produces superoxide at the expense of NO (Li and Forstermann, 2013; Li et al., 2013) and thus contributes to oxidative stress in PVAT (Xia et al., 2016).
The molecular mechanisms responsible for the increase in arginase and the subsequent L‐arginine deficiency observed in diet‐induced obesity remain to be determined. We propose that PVAT inflammation plays an important role in this effect. The expression/activity of vascular arginases can be enhanced by a variety of stimuli (Pernow and Jung, 2013), including Ang II (Shatanawi et al., 2011), high glucose (Romero et al., 2008), thrombin (Ming et al., 2004) and oxidized low‐density lipoprotein (Ryoo et al., 2006), conditions that inevitably lead to vascular inflammation.
To ascertain that eNOS uncoupling is causally involved in obesity‐induced vascular dysfunction, we incubated PVAT‐containing aorta with a combination of L‐arginine and an arginase inhibitor for 30 min ex vivo in organ chambers. This treatment had no effect on acetylcholine‐induced vasodilatation in aorta from control mice, but restored the vasodilator effects of PVAT‐containing aortas from HFD‐fed mice, indicating that L‐arginine deficiency is indeed a reason for PVAT eNOS dysfunction (Xia et al., 2016).
Another mechanism for PVAT eNOS dysfunction is the reduced phosphorylation of eNOS at the serine 1177 residue associated with Akt inhibition (one of the upstream kinases for serine 1177 phosphorylation) (Xia et al., 2016). In a recent study, we treated diet‐induced obese mice with the standardized Crataegus extract WS® 1442, which is known to enhance eNOS phosphorylation at the serine 1177 residue by stimulating Akt activity. The in vivo treatment with WS® 1442 improved the phosphorylation levels of Akt and eNOS, and completely normalized the vasodilator response of PVAT‐containing aorta from diet‐induced obese mice, confirming the functional importance of the Akt‐eNOS axis in obesity‐induced PVAT dysfunction (Xia N et al. unpublished data 2016).
In addition, obesity has been shown to reduce eNOS expression in mesenteric PVAT of diet‐induced obese rats (Bussey et al., 2016) and mice (Gil‐Ortega et al., 2014). Sustained weight loss in rats restores eNOS expression and improves PVAT NO production (Bussey et al., 2016). In severely obese individuals, bariatric surgery improves NO bioavailability in PVAT of small subcutaneous arteries (Aghamohammadzadeh et al., 2013).
In a rat model of obesity and metabolic syndrome (cafeteria diet, fed for 3 months), treatment with the PPARγ agonist rosiglitazone increases insulin sensitivity, reduces fasting insulin levels and triglyceride concentration, increases CSE expression and activity as well as PVAT H2S production, and improves the anticontractile effect of PVAT on aortic rings (Beltowski, 2013).
After treatment of rats for 3 weeks with lipophilic atorvastatin (20 mg·kg–1·day−1), but not hydrophilic pravastatin (40 mg·kg−1·day−1), the PVAT H2S levels were increased as its mitochondrial oxidation was inhibited, and the anticontractile effect of PVAT was augmented (Wojcicka et al., 2011). Inhibition of H2S metabolism results from the atorvastatin‐induced decrease in coenzyme Q, which is a cofactor of H2S oxidation by sulfide:quinone oxidoreductase. In contrast to H2S, statins do not impair mitochondrial oxidation of organic substrates (Beltowski and Jamroz‐Wisniewska, 2012). The effect of atorvastatin on PVAT H2S levels is independent of the lipid‐lowing action of the drug because both statins at the doses used had comparable effects on the plasma lipid profile. Hydrophilic statins act mainly in the liver whereas lipophilic statins are equally active in hepatocytes and extrahepatic tissues (Shitara and Sugiyama, 2006) and are supposed to accumulate in triglyceride‐rich PVAT (Beltowski, 2013). The effect of statins on PVAT function has not yet been verified in obesity models. Atorvastatin has been shown to improve PVAT function in spontaneously hypertensive rats (Zeng et al., 2009). It is not yet clear whether these effects are mediated by H2S.
In addition, cannabinoid CB1 receptor agonists elevate PVAT H2S by inhibiting its mitochondrial oxidation (Beltowski, 2013). The imidazoline I1 receptor agonist moxonidine has been shown to increase myocardial CSE expression and H2S production in streptozotocin‐induce diabetic rats (El‐Sayed et al., 2016).
Sulfhydrylated ACE inhibitors may be of particular interest because of their dual properties: inhibition of ACE and potentiation of the H2S pathway in vivo, as shown for S‐zofenopril in spontaneous hypertensive rats (Bucci et al., 2014).
In wire myograph experiments with rat mesenteric small arteries, the in vitro creation of a hypoxic environment causes the loss of PVAT's anticontractile function. This hypoxia‐induced loss of PVAT's anticontractile effect can be prevented by incubation with the ACE inhibitor captopril or the AT1 receptor antagonist termisartan (Rosei et al., 2015), or with the aldosterone antagonist eplerenone (Withers et al., 2011), whereas the β‐blocker atenolol was without effect (Rosei et al., 2015). Mechanistically, the renin–angiotensin–aldosterone system (RAAS) is thought to play a key role in the exacerbation of the hypoxia‐induced inflammation and oxidative stress. Hypoxia stimulates ROS production and may activate RAAS by up‐regulating ACE expression and inhibiting ACE2 activity (Zhang et al., 2009). Ang II and aldosterone enhance oxidative stress, macrophage infiltration and inflammation (Withers et al., 2011; Rosei et al., 2015). Both Ang II and mitoROS are potent activators of HIF‐1α (Patten et al., 2010). In vivo treatment with the AT1 receptor antagonist losartan improves PVAT function in fructose‐induced hypertensive rats (Huang et al., 2010). The aldosterone antagonist spironolactone has also been shown to restore PVAT function in a rat model of β‐adrenoceptor overstimulation (Victorio et al., 2016a). Nevertheless, the effect of RAAS inhibitors on PVAT function has not been tested in obesity models in vivo so far.
Chronic administration of melatonin has been shown to reduce body weight, circulating insulin, glucose and triglyceride serum levels in HFD‐fed rats (Prunet‐Marcassus et al., 2003; Rios‐Lugo et al., 2010). In the leptin‐deficient ob/ob mice, the anticontractile function of mesenteric PVAT is reduced (Agabiti‐Rosei et al., 2014). Treatment with melatonin in the drinking water for 8 weeks improves PVAT function. Importantly, melatonin improves vascular function only in the presence of PVAT, indicating the importance of PVAT in the vascular dysfunction observed in ob/ob mice (Agabiti‐Rosei et al., 2014). The improvement of PVAT function by melatonin is likely to be attributable to its antioxidant/anti‐inflammatory properties. Melatonin reduces the expression of ET‐1, IL‐6 and metalloproteases 2 and 9 in the aorta, decreases TNF‐α and CD68 levels in visceral fat and increases the expression of adiponectin and adiponectin receptor 1 in PVAT of ob/ob mice (Agabiti‐Rosei et al., 2014).
Cytokine antagonists also represent attractive anti‐inflammatory approaches. Ex vivo incubation with the anti‐TNF‐α antibody infliximab has been shown to improve PVAT function and PVAT NO production in small arteries isolated from obese patients (Virdis et al., 2015). The effect of in vivo anti‐TNF‐α therapy on PVAT function has not been reported, so far.
In vitro treatment of PVAT from rat thoracic aorta with AMPK activators AICAR, salicylate, metformin, resveratrol or diosgenin down‐regulates the expression of pro‐inflammatory factors (TNF‐α, IL‐6 and MCP‐1) and increases anti‐inflammatory molecules (adiponectin and PPARγ) in PVAT (Sun et al., 2014; Chen et al., 2016). This is associated with an improvement in eNOS phosphorylation and PVAT function (Sun et al., 2014; Chen et al., 2016).
Fructose‐feeding in rats leads to a dysregulation of adipokine/cytokine expression in plasma and PVAT, accompanied by a vascular dysfunction. Oral administration of fructose‐fed rats with resveratrol and metformin improves adipokine/cytokine profiles, enhances AMPK activity and SIRT1 expression in PVAT, and restores PVAT eNOS phosphorylation and acetylcholine‐induced vasodilatation (Sun et al., 2014). Importantly, in vitro treatment of aortic rings from normal rats with conditioned media of PVAT from fructose‐fed rats reduces acetylcholine‐induced vasodilatation. This inhibition of vascular function is reversed by conditioned media of PVAT from resveratrol‐ or metformin‐treated rats (Sun et al., 2014), indicating the key role of PVAT in the improvement of vascular function by the two compounds.
In HFD‐fed rats, oral administration of diosgenin or resveratrol normalizes PVAT size, restores PVAT expression of TNF‐α, IL‐6, MCP‐1, adiponectin, PPARγ and PVAT eNOS phosphorylation. Diosgenin and resveratrol also restores the effect of PVAT on vascular function (Chen et al., 2016). In contrast to these stimulating effects of diosgenin or resveratrol, another natural compound, genistein, showed no beneficial effects on PVAT despite preventing weight gain in obese ob/ob mice (Simperova et al., 2016).
A recent meta‐analysis demonstrates a significant increase in plasma adiponectin levels following statin therapy (Chrusciel et al., 2016). Adiponectin release from PVAT can be enhanced by stimulating the eNOS‐NO‐cGMP‐PKG pathway (Weston et al., 2013; Withers et al., 2014b). Thus, the mechanisms of statin‐induced adiponectin secretion may involve vascular NO production (Forstermann and Li, 2011; Li and Forstermann, 2014). Theoretically, PVAT adiponectin release may also be stimulated by activators of eNOS, sGC or PKG. As PPARγ plays a role in governing adiponectin expression (Antonopoulos et al., 2015b), PPARγ agonists (e.g. glitazones) and AMPK activators may enhance the expression of adiponectin in vivo, in addition to their effects on PVAT H2S production (see above). However, these concepts remain speculations at this stage. The effect of such approaches on adiponectin expression/release and PVAT function need to be investigated in future studies.
PVAT plays a crucial role in obesity‐induced vascular dysfunction. Hypoxia, inflammation and oxidative stress in PVAT lead to an impairment in the release of vasoactive factors from PVAT, and the normal anticontractile function of PVAT is lost in obesity. PVAT may, therefore, represent a new therapeutic target for vascular complications in obesity. Various approaches have been shown to improve PVAT function; however, their therapeutic potential needs to be further verified in obesity models.
N.X. and H.L. wrote the manuscript. Both authors agreed to its publication.
The authors declare no conflicts of interest.
This study was supported by the university intramural grant Stufe I of Johannes Gutenberg University Medical Center, Mainz, Germany.
Xia N., and Li H. (2017) The role of perivascular adipose tissue in obesity‐induced vascular dysfunction. British Journal of Pharmacology, 174: 3425–3442. doi: 10.1111/bph.13650.